SLX PRO MY ASS @SLXGrinders@Billyslx YOU LIE you say it doesnt chip, you say it doesn't stick YOU LIE your product has literally assaulted me #WTF it also gets stuck ALL the time. You think I want to eat paint chips with my weed? Very disappointed. #SLXgrinders#SLX#FRAUDULENT
$SLXN < $.15c - Silexion Therapeutics
🔹To enact a 1:24 R/S Nov 11
🔹New OS LESS than 1M shares
🔹To regain compliance with Nasdaq’s minimum bid price requirement
🔹Silexion is progressing through its Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, with the first patient dosed in September.
Silexion completes 1-for-24 reverse split to regain Nasdaq compliance
Silexion Therapeutics completed a 1-for-24 reverse share split effective November 10, 2026, raising par value to $3.24 per share.
$SLXN
$SLXN Share Split Announcement:
Silexion Therapeutics Corp announced a 1-for-24 reverse share split effective November 10, 2026, increasing the par value from $0.135 to $3.24 per share. The change will affect all issued and outstanding ordinary shares, commencing trading on a reverse split-adjusted basis on November 11, 2026.
(Visit stockinsights dot ai for full context)
$SLXN completed a 1-for-10 reverse share split in May 2026. Six months later, Silexion Therapeutics Corp. is executing a second one: 1-for-24, effective after market close on November 10, 2026.
Two reverse splits in a single calendar year reflects the sustained pressure on the company's bid price, and it surfaces something important for investors trying to understand what is actually happening at Silexion right now.
The company is not at a standstill. Its Phase 2/3 trial of SIL204, an RNA interference therapy for locally advanced pancreatic cancer targeting KRAS mutations, is active. The first patient was dosed in September. The trial design calls for a safety run-in cohort of approximately 18 patients, followed by a randomized expansion cohort of approximately 166 patients. Regulatory clearance has been obtained in both Israel and Germany.
The 1-for-24 consolidation is intended to bring the share price into compliance with Nasdaq's minimum bid price rule and, critically, to open the door for equity financings that fund the clinical program. Those two things are connected.
The next read that matters from SLXN is not the split mechanics. It is the first clinical update from the Phase 2/3 safety run-in cohort, which will give investors their first look at SIL204's profile in actual patients.
_
Disclosure: This content is not financial or investment advice. Silexion Therapeutics Corp. is a paid subscriber to Wall Street Wire's coverage and distribution platform. Full disclosure:
What does it actually take to keep $SLXN listed on Nasdaq while a Phase 2/3 clinical trial is running? In 2026, Silexion Therapeutics Corp. is providing the answer in real time.
Silexion today announced a 1-for-24 reverse share split, effective after market close on November 10, 2026. Shares begin trading on a split-adjusted basis at market open on November 11.
The reverse split targets compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement. Par value increases from $0.135 to $3.24 per share proportionately. No fractional shares are issued. DTC participants get rounded up.
Here is what most commentary on this release will skip: the company's Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer is not future-tense. The first patient was dosed in September 2026 at Tel Aviv Sourasky Medical Center. The trial includes a safety run-in cohort of approximately 18 patients and a randomized expansion cohort of approximately 166 patients. Germany's BfArM and the Israeli Ministry of Health have both cleared the trial. The reverse split is also explicitly intended to facilitate equity financings that support continued clinical execution.
Next catalyst to watch: the completion of the Phase 2/3 safety run-in cohort and the first clinical data update from the SIL204 program. That will be the moment that shifts the narrative from listing mechanics to clinical outcomes.
_
Disclosure: This content is not financial or investment advice. Silexion Therapeutics Corp. is a paid subscriber to Wall Street Wire's coverage and distribution platform. Full disclosure:
Today's PRs 3/5, offerings, splits and listings
— $LFST prices a 45M share secondary at $13.12, company sells nothing and buys back 2M shares
— $GPUS plans an exchange offer for up to $50M of stock, $2.00 cash plus a preferred per 100 shares
— $SLXN 1-for-24 reverse split, trades adjusted from Nov 11
— $CISS 1-for-5, $SMX 2.8-for-1 and $ARAY 1-for-40 start trading split-adjusted today
— $NCPL gets a Nasdaq extension until Feb 9 to file its overdue reports
Not financial advice.
Share
Copied
StocksDaily@IntradayRider
Today's PRs 2/5, biotech and FDA
— $IBRX ANKTIVA plus BCG meets the primary endpoint in the QUILT-2.005 bladder cancer trial
— $VIR Phase 3 ECLIPSE 1 hits its primary endpoint in hepatitis D, 44.1% undetectable virus and normalized ALT
— $NVCR FDA issues a Not Approvable Letter for Optune Mya in brain metastases
— $ZURA Phase 2 trial of tibulizumab in HS fails its primary endpoint, development in HS stops
— $EDSA signs a Japan license with Kyorin, $12M upfront and up to about $134M in milestones
— $MEDS first commercial sale of a compounded peptide under HHS's enforcement policy
Not financial advice.
Today's PRs 2/5, biotech and FDA
— $IBRX ANKTIVA plus BCG meets the primary endpoint in the QUILT-2.005 bladder cancer trial
— $VIR Phase 3 ECLIPSE 1 hits its primary endpoint in hepatitis D, 44.1% undetectable virus and normalized ALT
— $NVCR FDA issues a Not Approvable Letter for Optune Mya in brain metastases
— $ZURA Phase 2 trial of tibulizumab in HS fails its primary endpoint, development in HS stops
— $EDSA signs a Japan license with Kyorin, $12M upfront and up to about $134M in milestones
— $MEDS first commercial sale of a compounded peptide under HHS's enforcement policy
Not financial advice.
$SLXN Silexion Therapeutics, 1-for-24 reverse split, trades split-adjusted from Nov 11
— Effective after the close on Nov 10, same ticker, new CUSIP
— Aim is to regain Nasdaq's minimum bid price, it also has a minimum shareholders' equity deficiency
— Clinical-stage KRAS cancer biotech, dosed its first patient in the Phase 2/3 SIL204 pancreatic cancer trial in September
— Risk: split also makes equity raises easier, so expect dilution, and it has not yet fixed its Nasdaq deficiencies
Not financial advice.
Compact. Capable. Proven. ✅
The SLx® 3X MicroPrism™ brings together compact performance, sharp clarity, and a finish that looks right at home on your favorite setup.
Grab yours today via
#PrimaryArmsOptics#SLx#MicroPrism#Precision
